North America injectable drug delivery market is expected to reach USD 354.5 billion by 2024 from USD 154.0 billion in 2016, at a CAGR of 11.0% in the forecast period 2017 to 2024. The report contains 289 pages of exclusive premium insights with 135 tables and 46 figures.

Please continue to read the complete report at : https://www.bharatbook.com/healthcare-market-research-reports-920962/north-america-injectable-drug-delivery-industry-trends.html

North America injectable drug delivery market is segmented on the basis of type, applications, usage pattern, mode of administration, end user, and country.

Request A Sample copy of North America Injectable Drug Delivery Market @ https://www.bharatbook.com/request-sample/920962

On the basis of applications, the injectable drug delivery market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases, and others.

Based on indications, the market is segmented into rheumatoid arthritis, multiple sclerosis, Crohn’s disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis, and others.

The North America Injectable Drug Delivery Market is segmented into 3 major countries such as U.S., Canada, Mexico

Major Players Operating in North America Injectable Drug Delivery Market:

Baxter International, Inc., Becton, Dickinson and Company, Gerresheimer AG, Pfizer, Inc., Schott AG, Alkermes Plc., Eli Lilly and Company, Sandoz, Terumo Corporation, and Teva Pharmaceuticals Industries Ltd., among others.

Regions Covered In The Scope Of The Report:

North America (U.S., Canada, Mexico)

Table Of Contents

1 INTRODUCTION
1.1. OVERVIEW OF NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED
2.MARKET SEGMENTATION
3.2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.7. SECONDARY SOURCES
2.8. ASSUMPTION
3. MARKET OVERVIEW
3.1. DRIVERS
3.1.1. RISING CASES OF CHRONIC DISEASES
3.1.2. RISING DEMAND OF SELF-INJECTION DEVICES
3.1.3. GROWTH OF BIOLOGICS MARKET
3.1.4. TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN DRUG DELIVERY MARKET
3.2. RESTRAINTS
3.2.1. NEEDLESTICK INJURIES AND INFECTIONS
3.2.2. HIGH COST OF DEVELOPMENT
3.2.3. STRICT REGULATORY FRAMEWORK
3.3. OPPORTUNITY
3.3.1. INCREASING DEMAND FOR GENERIC AND BIOSIMILAR DRUGS
3.3.1.1. GENERICS
3.3.1.2. BIOSIMILARS
3.3.2. INCREASING DEMAND FOR CONTRACEPTIVE INJECTABLES
3.3.3. INCREASING DEMAND FOR SELF-ADMINISTRATION OF DRUGS
3.4. CHALLENGES
3.4.1. ALTERNATIVE ROUTE OF DRUG ADMINISTRATION
3.4.2. PRODUCT RECALL
3.4.3. STABILITY OF PRODUCTS
3.4.4. STERILITY OF INJECTIONS